Target Name: CD99
NCBI ID: G4267
Review Report on CD99 Target / Biomarker Content of Review Report on CD99 Target / Biomarker
CD99
Other Name(s): cell surface antigen 12E7 | MSK5X | E2 antigen | antigen identified by monoclonal 12E7, Y homolog | CD99_HUMAN | Antigen identified by monoclonal antibodies 12E7, F21 and O13 | Protein MIC2 | MIC2 (monoclonal antibody 12E7) | cell surface antigen HBA-71 | surface antigen MIC2 | MIC2 | CD99 variant 1 | 12E7 | antigen identified by monoclonal antibodies 12E7, F21 and O13 | CD99 molecule (Xg blood group), transcript variant 1 | CD99 molecule (Xg blood group) | HBA71 | MIC2X | MIC2Y | CD99 antigen (isoform a) | Antigen identified by monoclonal 12E7, Y homolog | CD99 antigen | T-cell surface glycoprotein E2 | cell surface antigen O13

CD99: A Potential Drug Target and Biomarker for Cancer

Introduction

CD99 is a cell surface antigen located on the protein CD99, which is expressed in various tissues and cells, including hematopoietic stem cells, natural killer cells, and cancer cells. CD99 has been identified as a potential drug target and biomarker for cancer due to its unique expression pattern and biological functions. In this article, we will discuss the biology and potential therapeutic applications of CD99.

CD99: A cell surface antigen and its functions

CD99 is a 26kDa cell surface antigen that is expressed in various tissues and cells, including blood vessels, epithelial cells, endothelial cells, natural killer cells, and cancer cells. It is composed of a cytoplasmic region and a transmembrane region that contains a N- terminal alpha-helix, a central alpha-helices region, and a C-terminal T-loop. CD99 functions as a cell adhesion molecule, playing a role in the regulation of cell-cell and cell-tissue interactions.

CD99 has been shown to participate in various cellular processes, including cell adhesion, migration, and invasion. Studies have shown that CD99 promotes the formation of tight junctions and adherens junctions, which are essential for the maintenance of tissue structure and function. In addition, CD99 has been shown to contribute to the development and progression of various cancers, including breast, lung, and ovarian cancer.

Potential therapeutic applications of CD99

CD99 has been identified as a potential drug target for cancer due to its unique expression pattern and biological functions. The potential therapeutic applications of CD99 include the following:

1. CD99 as a drug target
CD99 has been shown to be a potential drug target for cancer due to its unique expression pattern and functions. Activation of CD99 has been shown to promote the growth and survival of various cancer cells, making it an attractive target for cancer therapies.
2. CD99 as a biomarker
CD99 has been shown to be a potential biomarker for cancer due to its unique expression pattern and functions. The expression of CD99 has been shown to be associated with the severity of cancer and the response to various cancer therapies.

CD99 targeting strategies

Several strategies have been proposed to target CD99 and its functions, including the following:

1. Monoclonal antibodies
Monoclonal antibodies (MAs) have been shown to be effective in targeting CD99 due to their ability to recognize a specific protein and their ability to selectively bind to it. MAs have been shown to be effective in targeting CD99 and have been used in various clinical trials for cancer treatment.
2. Peptide-conjugated nanoparticles
Peptide-conjugated nanoparticles have been shown to be effective in targeting CD99 due to their ability to bind to specific proteins and their ability to protect nanoparticles from degradation and clearance by the body. These nanoparticles have been shown to be effective in delivering small molecules, including drugs, to cancer cells.
3. DNA-based therapies
DNA-based therapies have been shown to be effective in targeting CD99 due to their ability to deliver genetic information to cancer cells and their ability to silence the expression of CD99.

Conclusion

CD99 has been identified as a potential drug target and biomarker for cancer due to its unique expression pattern and biological functions. The potential therapeutic applications of CD99 include the regulation of cell-cell and cell-tissue interactions, the development and progression of various cancers, and the targeting of cancer cells. CD99 has also been shown to be a potential target for monoclonal antibodies, peptide-conjugated nanoparticles, and DNA-based therapies. Further research is needed to fully understand the potential

Protein Name: CD99 Molecule (Xg Blood Group)

Functions: Involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. Plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Involved in T-cell adhesion processes (By similarity)

The "CD99 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD99 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2